Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Group 1 - Beam Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results along with a new liver-targeted genetic disease program on February 24, 2026 [1] - The live webcast of the announcement will be available on the company's investor section of its website and will be archived for 60 days [2] Group 2 - Beam Therapeutics is focused on developing precision genetic medicines through base editing, which allows for precise and efficient single base changes in DNA without double-stranded breaks [3] - The company has established a fully integrated platform for gene editing, delivery, and internal manufacturing capabilities, aiming to provide lifelong cures for patients with serious diseases [3]